ALSP, Inc., Appoints Michael D. Pierschbacher as President/CEO.San Diego Biotech Company Announces NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. Funding and Key Results SAN DIEGO -- ALSP ALSP Aggregate Level Simulation Protocol ALSP Acquisition Logistics Support Plan ALSP Atmosphere and Land Surface Processes ALSP Army Logistics Study Program , Inc. (American Life Science Pharmaceuticals) announced today that it has been awarded a $296,000 R21 grant from the National Institute on Aging The National Institute on Aging is a division of the U.S. National Institutes of Health, located in Bethesda, Maryland. Formed in 1974, NIA's mission is to improve the health and well-being of older Americans through research. It is the primary U.S. , National Institutes of Health (NIH) to support the development of its drug to treat Alzheimer's disease. The Company also announced the addition of Michael D. Pierschbacher, Ph.D., to its staff as President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . Pierschbacher succeeds former CEO, Steve Richieri, who will retain his position as Chairman of the Board. Dr. Pierschbacher brings more than 20 years experience in product development in the biotech industry to the ALSP team. Dr. Pierschbacher served most recently as senior vice president, R&D for Integra LifeScience Corp., a New Jersey-based medical device company and as the director of Integra's Corporate Research Center in San Diego. Dr. Pierschbacher will also join the Board of Directors, which currently consists of four other individuals with extensive experience in the pharmaceutical arena (see www.alspinc.com). "This grant is based on pioneering work from the Company's Scientific Founder, Professor Vivian Hook, Ph.D., at The Skaggs School of Pharmacy and Pharmaceutical Sciences, UCSD. Significant results from this work were just published in the February issue of Biological Chemistry," Dr. Pierschbacher commented. "This money will augment the Company's other funding and help move this remarkable new discovery rapidly to the clinic. I am honored to be joining this talented team at this exciting time in the Company's history." The publication is titled "Cysteine cysteine (sĭs`tēn), organic compound, one of the 20 amino acids commonly found in animal proteins. Only the l-stereoisomer participates in the biosynthesis of mammalian protein. protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease" (Biol. Chem. 388, 247-252). About ALSP, Inc. ALSP, Inc. (American Life Science Pharmaceuticals, Inc.) is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. based in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. , initially focused on developing new small molecule drugs for treating Alzheimer's disease. Our approach is to identify key enzymes in the brain, called neuroproteases, which produce biologically active peptides that are thought to cause the disease. We then use those enzymes as targets screening compounds that inhibit the neuroproteases and thereby reduce production of the harmful peptides and treat the disease. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion